Two-thirds of laboratories planning to purchase a sequencer within the next 12 months are considering Illumina's MiSeq, according to a recent survey by investment firm Mizuho Securities USA and GenomeWeb.

In the survey, conducted at the end of the first quarter, researchers ranked the Illumina MiSeq higher than the Ion Torrent PGM in seven out of 10 categories.

The HiSeq scored above the Ion Proton in five out of 10 areas, equal in two, and the Proton came out first in three categories.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.